Sun Biomedical Ltd., of West Perth, Australia, added a fourth site to its phase II study into the safety and efficacy of DMX-200, a chronic kidney disease candidate that combines the existing drugs, irbesartan and propagermanium. The single-arm, open-label trial includes a dose-escalation phase recruiting up to 30 patients and an expansion study in which up to 30 patients will be treated at the optimal identified dose.